You should not take Contrave if you: Have uncontrolled high blood pressure Have anorexia or bulimia Have or have had seizures Use other medicines that contain bupropion such as Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin, or Zyban Are undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs Drink a lot of alcohol and abruptly stop drinking Have kidney disease Have liver disease (it may cause liver dysfunction or hepatitis) Are depressed or have suicidal feelings Have current or recent (within the past 7-14 days) use of opioids or opiate drugs You should not take Contrave under these circumstances either: If youre pregnant, breastfeeding, or planning to become pregnant If youve taken an MAOI (monoamine oxidase inhibitor), such as Nardil, Parnate, or Marplan in the past 14 days If youre taking any opioids or opiate drugs If youre dependent on opioids or using methadone or buprenorphine If you are in opioid withdrawal If you take opioids or opiates right after stopping Contrave, you may be more sensitive to them and require lower doseswhich poses a risk of overdose
Ideal Candidates for Tesofensine Therapy While Tesofensine is not yet FDA-approved for any indication, ongoing research suggests that it may hold promise as a potential treatment option for individuals with obesity who have not achieved significant weight reduction through lifestyle modifications alone
& Zhao, Z
Semaglutide patent loss opens up a $6 billion opportunity for Indian generic drug makers ADVERTISEMENT The world's second-largest-selling drug - Novo Nordisks anti-diabetes/weight management drug semaglutide (branded as Ozempic and Wegovy) - is set to lose patent protection in several countries this year, including in India, China, Canada, and Brazil, starting in the fourth week of March
